Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
This study sheds light on the expected outcome of relapsed myeloma patients that are refractory to a PI and an IMiD.
72 Hours, 5 Countries: A Snapshot of the International Myeloma Foundation’s Global Impact
Week in Review
Food Marketing Reaches a New Low: Buyers Beware
Week in Review
PET/CT Scanning Comes of Age: New IMWG Guidelines Published
Week in Review
